| Title |
Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy
|
|---|---|
| Published in |
Cochrane database of systematic reviews, November 2014
|
| DOI | 10.1002/14651858.cd008721.pub2 |
| Pubmed ID | |
| Authors |
Maria José Martinez‐Zapata, Arturo J Martí‐Carvajal, Ivan Solà, José I Pijoán, José A Buil‐Calvo, Josep A Cordero, Jennifer R Evans |
| Abstract |
Proliferative diabetic retinopathy (PDR) is a complication of diabetic retinopathy that can cause blindness. Although panretinal photocoagulation (PRP) is the treatment of choice for PDR, it has secondary effects that can affect vision. An alternative treatment such as anti-vascular endothelial growth factor (anti-VEGF), which produces an inhibition of vascular proliferation, could improve the vision of people with PDR. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 212 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| China | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 208 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 34 | 16% |
| Researcher | 27 | 13% |
| Student > Bachelor | 25 | 12% |
| Student > Ph. D. Student | 19 | 9% |
| Other | 14 | 7% |
| Other | 38 | 18% |
| Unknown | 55 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 91 | 43% |
| Nursing and Health Professions | 16 | 8% |
| Biochemistry, Genetics and Molecular Biology | 7 | 3% |
| Computer Science | 6 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 3% |
| Other | 23 | 11% |
| Unknown | 63 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 December 2014.
All research outputs
#20,723,696
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#10,914
of 11,842 outputs
Outputs of similar age
#274,938
of 369,825 outputs
Outputs of similar age from Cochrane database of systematic reviews
#240
of 256 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 369,825 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 256 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.